

29<sup>th</sup> July 2022

- |   |  |
|---|--|
| <p>(1) BSE Limited<br/>Listing Department,<br/>Phiroze Jeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai 400 001</p> <p><b>Scrip Code: 500087</b></p> | <p>(2) National Stock Exchange of India Limited<br/>Listing Department<br/>Exchange Plaza, 5<sup>th</sup> floor,<br/>Plot no. C/1, G Block,<br/>Bandra Kurla Complex,<br/>Bandra (East), Mumbai - 400 051</p> <p><b>Scrip Code: CIPLA EQ</b></p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG<br/>Societe Anonyme<br/>35A Boulevard Joseph II,<br/>L-1840 Luxembourg</p>                                |  |

**Sub: Appointment of Dr. Mandar Purushottam Vaidya as an Independent Director**

Dear Sir / Madam,

In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we hereby notify that on the recommendation of the Nomination and Remuneration Committee and subject to the approval of the shareholders at the ensuing Annual General Meeting, the Board of the Directors at its meeting held today i.e., on 29<sup>th</sup> July 2022, has appointed Dr. Mandar Purushottam Vaidya (DIN: 09690327) as an additional and independent director of the Company for a period of 5 years with effect from 29<sup>th</sup> July 2022 to 28<sup>th</sup> July 2027 (both days inclusive).

The details as required under the SEBI Listing Regulations read with the SEBI Circular No. CIR/CFD/ CMD/ 4/ 2015 dated 9<sup>th</sup> September 2015 are given in Annexure A to this letter.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

**For Cipla Limited**



**Rajendra Chopra**

**Company Secretary**

Encl: As above

Prepared by: Chirag Hotchandani

**Annexure A**

<b>DIN</b>	09690327
<b>Name of Director</b>	Dr. Mandar Purushottam Vaidya
<b>Reason for change viz. appointment, resignation, removal, death or otherwise</b>	Appointment of Dr. Mandar Purushottam Vaidya, as additional and an independent director of the Company for a period of 5 years w.e.f. 29 <sup>th</sup> July 2022 to 28 <sup>th</sup> July 2027 (both days inclusive)
<b>Date of appointment / cessation (as applicable) &amp; term of appointment</b>	For period of 5 year commencing from 29 <sup>th</sup> July 2022 to 28 <sup>th</sup> July 2027
<b>Brief Profile</b>	<p>Dr. Mandar Vaidya is a medical doctor and a management graduate from the Jamnalal Bajaj Institute of Management Studies, India.</p> <p>He spent 15 years at McKinsey (2002-2017), the last seven as a partner where he co-led the healthcare practice in India and established the hospitals practice for Asia. He has served leading pharmaceutical companies in India and globally, across several areas such as core strategy, manufacturing productivity improvement, R&amp;D productivity, portfolio management, M&amp;A and procurement programs.</p> <p>From 2017 to 2019, he worked part time, advising several healthcare companies, providing leadership coaching and designing and teaching a course on problem solving at Ashoka University.</p> <p>In August 2019, he joined OYO, a global travel-tech company as CEO – SE Asia &amp; Middle East, driving growth, doubling the number of hotels and homes, while transforming the regions contribution margin to a net positive territory. He led the business through the COVID crisis, improving EBIDTA loss to a negligible level while managing massive business disruptions.</p> <p>Since March 2021 he is the CEO - OYO Vacation Homes (OVH), Europe, a strategically important core market for the company. OVH is Europe's second largest vacation homes company. He leads three acquired brands, DanCenter, Belvilla and Traum FW, each with a multi decade legacy. He has turbo charged their growth and profitability by migrating them into a tech forward environment while retaining the uniqueness of each business built over the last several decades.</p>
<b>Disclosure of relationships between directors (in case of appointment of a director).</b>	None
<b>Information as required pursuant to BSE Circular with ref. no. LIST/COMP/ 14/ 2018- 19 and the National Stock Exchange of India Ltd with ref. no. NSE/ CML/ 2018/24, dated 20<sup>th</sup> June 2018</b>	Dr. Mandar Vaidya is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.